Sustained API price weakness
API prices remain lower than last year despite recent uptick; further decline could delay turnaround and keep losses elevated.
high · management_commentaryAkums Drugs & Pharmaceuticals Ltd — Q4 FY26
Akums Drugs reported a strong Q4 FY26 with consolidated revenue of ₹1,158 crore (+9.7% YoY) and adjusted EBITDA of ₹152 crore (+61.6% YoY), driven by robust CDMO volume growth o...
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Execution risk in Zambia and European contracts
Delays in regulatory approvals or tech transfer could push back revenue recognition from these large contracts.
medium · analyst_questionGLP-1 market entry uncertainty
Management was evasive on GLP-1 strategy, citing pricing volatility; missing this opportunity could limit future growth.
medium · analyst_questionWorking capital increase
Working capital days rose from 91 to 105 due to inventory buildup; further increases could pressure cash flows.
low · data_observation